Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Rocket Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing gene therapy treatment options for undertreated diseases, genetic disease that leads to bone marrow failure and potentially cancer, and pediatric disease. Rocket Pharmaceuticals serves patients in the United States.
Website: rocketpharma.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 139.3% (LTM)

Entry Point: Share price is 2.8% higher than minimum and 93.0% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $0.4 mln (-0.185% of cap.)

Key Financials (Download financials)

Ticker: RCKT
Share price, USD:  (+2.8%)2.24
year average price 3.40  


year start price 4.00 2025-10-20

max close price 4.19 2026-07-09

min close price 2.18 2026-10-16

current price 2.24 2026-10-20
Common stocks: 68 148 925

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 149
Net Debt ($m): -237
EV (Enterprise Value): -88
Price to Book: 0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-24defenseworld.net

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why

2026-01-14seekingalpha.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-10-23globenewswire.com

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2025-10-15zacks.com

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

2025-10-14benzinga.com

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

2025-10-03reuters.com

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

2025-09-19prnewswire.com

Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

2025-09-09seekingalpha.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-21zacks.com

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

2025-08-20reuters.com

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-06 2024-05-07 2023-11-07 2023-08-09 2023-05-05 2022-11-04
acceptedDate 2025-11-06 16:06:46 2025-08-07 16:06:57 2025-02-27 16:01:32 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03 2022-02-28 16:10:02 2021-03-01 17:03:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 2M 2M 0 2M 2M 0 0 0 0 1M
grossProfit 0 0 0 0 -2M -2M 0 -2M -2M 0 0 0 0 -1M
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 34M 43M 171M 42M 45M 44M 186M 47M 51M 46M 166M 43M 125M 106M
generalAndAdministrativeExpenses 18M 25M 102M 27M 27M 22M 73M 19M 17M 16M 59M 15M 42M 28M
sellingAndMarketingExpenses 0 0 0 0 -786 000 -787 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 18M 25M 102M 27M 27M 21M 73M 19M 17M 16M 59M 15M 42M 28M
otherExpenses -172 000 3M 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 52M 71M 273M 69M 71M 65M 260M 65M 69M 62M 224M 58M 167M 135M
costAndExpenses 52M 71M 273M 69M 74M 67M 260M 65M 69M 62M 224M 58M 167M 136M
interestIncome 0 3M 18M 3M 5M 6M 16M 4M 4M 4M 4M 1M 3M 2M
interestExpense 473 000 473 000 2M 471 000 471 000 471 000 2M -469 000 468 000 468 000 2M 621 000 6M 8M
depreciationAndAmortization 3M 3M 9M 2M 2M 2M 7M 2M 2M 6M 6M 2M 5M 1M
ebitda -47M -66M -247M -64M -67M -65M -237M -65M -64M -56M -214M -56M -158M -132M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -52M -71M -273M -69M -74M -67M -260M -65M -69M -62M -224M -58M -167M -136M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 2M 2M 14M 3M 4M 5M 14M 4M 3M 4M 2M 732 000 -2M -4M
incomeBeforeTax -50M -69M -259M -67M -70M -62M -246M -62M -66M -58M -222M -58M -169M -140M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 1 0 -2M 4M -3M 0 -732 000 0 7M
netIncome -50M -69M -259M -67M -70M -62M -246M -62M -66M -55M -222M -57M -169M -147M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -0.45 -0.62 -2.73 -0.71 -0.74 -0.66 -2.92 -0.75 -0.82 -0.69 -3.26 -0.86 -2.68 -2.52
epsdiluted -0.45 -0.62 -0.71 -0.74 -0.66 -0.75 -0.82 -0.69 -0.86
weightedAverageShsOut 112M 111M 95M 94M 94M 94M 84M 83M 80M 79M 68M 66M 63M 55M
weightedAverageShsOutDil 112M 111M 95M 94M 94M 94M 84M 83M 80M 79M 68M 66M 63M 55M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-28 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 16M 14M 2M -3M -5M
ebit -257M -244M -220M -163M -133M
nonOperatingIncomeExcludingInterest -16M -16M -4M -4M -3M
netIncomeFromContinuingOperations -259M -246M -222M -169M -147M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 -7M
bottomLineNetIncome -259M -246M -222M -169M -140M
epsDiluted -2.73 -2.92 -3.26 -2.68 -2.52

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-06 2024-05-07 2023-11-07 2023-08-09 2023-05-05 2022-11-04
acceptedDate 2025-11-06 16:06:46 2025-08-07 16:06:57 2025-02-27 16:01:32 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03 2022-02-28 16:10:02 2021-03-01 17:03:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 76M 33M 164M 66M 39M 35M 56M 226M 45M 65M 141M 197M 233M 297M
shortTermInvestments 147M 239M 209M 170M 240M 295M 317M 212M 262M 267M 216M 110M 156M 186M
cashAndShortTermInvestments 223M 271M 372M 236M 279M 330M 373M 437M 307M 331M 356M 307M 389M 483M
netReceivables 0 0 0 0 8M 9M 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 5M 6M 6M 6M 6M 6M 5M 10M 5M 7M 8M 5M 0 0
totalCurrentAssets 228M 277M 378M 242M 293M 345M 378M 447M 312M 338M 364M 311M 392M 487M
propertyPlantEquipmentNet 74M 78M 83M 86M 88M 88M 88M 86M 83M 81M 78M 74M 72M 71M
goodwill 39M 39M 39M 39M 39M 39M 39M 39M 39M 39M 39M 31M 31M 31M
intangibleAssets 25M 25M 25M 25M 25M 25M 25M 25M 26M 26M 26M 0 0 0
goodwillAndIntangibleAssets 64M 64M 64M 64M 64M 64M 64M 64M 65M 65M 65M 31M 31M 31M
longTermInvestments 1M 0 0 0 1M 1M 34M 1M 1M 29M 43M 0 0 0
taxAssets 0 0 0 0 -1 0 0 -1M -1M 0 0 0 0 -2M
otherNonCurrentAssets 515 000 2M 2M 2M 481 000 533 000 2M 2M 2M 2M 2M 2M 2M 4M
totalNonCurrentAssets 140M 144M 150M 152M 154M 154M 188M 152M 150M 177M 188M 106M 105M 103M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 368M 421M 528M 394M 446M 499M 566M 599M 462M 515M 552M 417M 497M 591M
accountPayables 0 2M 0 0 0 3M 0 1853 1115 0 0 0 0 0
shortTermDebt 3M 3M 0 3M 6M 3M 0 3M 3M 3M 0 2M 0 5M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 -3M 0 -1853 -1115 0 0 0 0 590 000
otherCurrentLiabilities 28M 39M 12M 37M 32M 30M 10M 31M 31M 29M 10M 28M 5M 2M
totalCurrentLiabilities 31M 43M 41M 40M 38M 33M 49M 33M 34M 31M 39M 30M 22M 33M
longTermDebt 22M 22M 0 23M 23M 23M 0 22M 22M 23M 0 20M 0 35M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 1M 1M 1M 1M 2M 3M 2M 2M 2M 3M 17M 80 000 136 000
totalNonCurrentLiabilities 23M 23M 24M 24M 24M 25M 25M 24M 24M 25M 23M 20M 20M 55M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 22M 25M 25M 26M 26M 23M 25M 25M 25M 25M 23M 22M 23M 22M
totalLiabilities 54M 67M 64M 64M 62M 58M 74M 58M 59M 56M 62M 50M 42M 87M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1M 1M 1M 911 000 910 000 906 000 903 000 901 000 805 000 804 000 791 000 678 000 645 000 610 000
retainedEarnings -1 399M -1 348M -1 218M -1 158M -1 091M -1 021M -959M -900M -838M -772M -714M -647M -492M -323M
accumulatedOtherComprehensiveIncomeLoss -9000 -107 000 66 000 213 000 -218 000 -135 000 319 000 -508 000 -722 000 -90 000 -357 000 -596 000 -161 000 -42 000
othertotalStockholdersEquity 1 711M 1 702M 1 486M 1 475M 1 462M 1 440M 1 241M 1 230M 1 014M
totalStockholdersEquity 314M 354M 463M 330M 385M 442M 493M 541M 403M 459M 490M 367M 455M 504M
totalEquity 314M 354M 463M 330M 385M 442M 493M 541M 403M 459M 490M 367M 455M 504M
totalLiabilitiesAndStockholdersEquity 368M 421M 394M 446M 499M 599M 462M 515M 417M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 368M 421M 528M 394M 446M 499M 566M 599M 462M 515M 552M 417M 497M 591M
totalInvestments 148M 239M 209M 170M 242M 296M 352M 212M 262M 29M 259M 110M 156M 186M
totalDebt 25M 25M 25M 26M 26M 26M 25M 25M 25M 25M 23M 22M 23M 62M
netDebt -51M -8M -138M -40M -13M -9M -31M -200M -20M -39M -118M -175M -210M -235M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-28 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 3M 5M
totalPayables 0 13M 597 000 597 000 590 000
otherPayables 0 13M 597 000 597 000 590 000
accruedExpenses 26M 23M 26M 14M 22M
capitalLeaseObligationsCurrent 3M 3M 3M 3M 2M
capitalLeaseObligationsNonCurrent 23M 22M 20M 20M 19M
treasuryStock 0 0 -47 000 0 0
additionalPaidInCapital 1 680M 1 451M 1 203M 946M 826M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT RCKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-06 2024-05-07 2023-11-07 2023-08-09 2023-05-05 2022-11-04
acceptedDate 2025-11-06 16:06:46 2025-08-07 16:06:57 2025-02-27 16:01:32 2024-11-07 16:45:24 2024-08-06 16:15:31 2024-05-07 16:05:55 2024-02-27 16:05:52 2023-11-07 16:40:36 2023-08-09 17:21:03 2023-05-05 16:41:24 2023-02-28 17:31:33 2022-11-04 16:07:03 2022-02-28 16:10:02 2021-03-01 17:03:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -50M -69M -259M -67M -70M -62M -246M -62M -66M -58M -222M -58M -169M -140M
depreciationAndAmortization 3M 3M 9M 2M 2M 2M 7M 2M 2M 2M 6M 1M 5M 1M
deferredIncomeTax 0 0 0 0 0 0 0 12M 0 0 0 0 3M 999 000
stockBasedCompensation 10M 11M 44M 11M 11M 10M 39M 10M 10M 9M 31M 8M 29M 19M
changeInWorkingCapital -11M 9M 2M 248 000 4M -5M 13M -6M 5M -7M 6M 4M -3M 15M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 -2M 0 0 0 -8M 10M 0 -5M 11M
otherWorkingCapital -11M 9M 2M 248 000 4M -5M 13M -6M 5M 8M -4M 0 1M 4M
otherNonCashItems -2M -2M -6M 755 000 14M 12M -9M -14M -2M -2M 370 000 690 000 14M 29M
netCashProvidedByOperatingActivities -50M -49M -210M -52M -54M -57M -195M -57M -51M -58M -178M -44M -121M -75M
investmentsInPropertyPlantAndEquipment 54 000 -50 000 -6M -2M -2M -2M -16M -5M -4M -3M -9M -503 000 -8M -29M
acquisitionsNet 0 0 0 0 0 0 0 -52 909 -35 325 7000 43M 0 95 000 8M
purchasesOfInvestments -29M -53M -246M -19M -39M -64M -391M -13M -73M -96M -376M -34M -246M -209M
salesMaturitiesOfInvestments 123M 85M 383M 100M 96M 101M 309M 66M 108M 62M 273M 58M 272M 142M
otherInvestingActivites 0 0 0 0 37 069 52 909 35 325 -7000 0
netCashUsedForInvestingActivites 94M 32M 79M 56M 35M 48M 31M -37M 23M
debtRepayment 8000 13 000 0 29 000 -27 000 -35 000 -37 000 0 0
commonStockIssued 0 215 000 176 000 2M 1M 189M 182 000 18M 30M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 -47 000 0 0 -72 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -67 000 -13 000 120 000 0 1184 35 000 37 000 7000 0
netCashUsedProvidedByFinancingActivities -59 000 215 000 120 000 2M 1M 189M 182 000 18M 30M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 -167M 0 0 0 0 0 0
netChangeInCash 43M -17M 108M 27M 3M -21M -85M 181M -19M -76M -92M 9M -65M 112M
cashAtEndOfPeriod 76M 34M 165M 67M 39M 35M 57M 227M 46M 66M 142M 198M 234M 299M
cashAtBeginningOfPeriod 33M 51M 57M 40M 35M 56M 142M 46M 66M 142M 234M 189M 299M 187M
operatingCashFlow -50M -49M -210M -52M -54M -57M -195M -57M -51M -58M -178M -44M -121M -75M
capitalExpenditure 54 000 -50 000 -6M -2M -2M -2M -16M -5M -4M -3M -9M -503 000 -8M -29M
freeCashFlow -50M -49M -216M -54M -56M -59M -211M -62M -55M -61M -187M -44M -129M -104M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-02-28 2022-02-28 2021-03-01
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -95 000 -8M
netCashProvidedByInvestingActivities 132M -98M -69M 19M -97M
netDebtIssuance 0 139 000 172 000 201 000 6M
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 139 000 172 000 201 000 6M
netStockIssuance 186M 208M 155M 38M 281M
netCommonStockIssuance 186M 208M 155M 38M 281M
commonStockIssuance 186M 208M 155M 38M 281M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -132 000 -172 000 -201 000 -4M
netCashProvidedByFinancingActivities 186M 208M 155M 38M 283M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2026-08-10 ET
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
2026-08-03 ET
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
2026-06-12 ET
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
2026-05-28 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-07 20:00 ET
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2026-04-28 11:00 ET
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
2026-03-27 ET
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2026-02-26 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
2026-02-23 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-01-05 ET
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 ET
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-06 ET
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
2025-10-14 ET
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2025-10-10 ET
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-28 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-08-20 ET
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
2025-08-07 ET
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
2025-08-03 ET
AUGUST 11 DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
2025-07-30 ET
SHAREHOLDER DEADLINE: Rocket Pharmaceuticals (RCKT) Investors Are Reminded of Deadline in Securities Action
2025-07-26 ET
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
2025-07-24 ET
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
2025-07-23 ET
Investor Alert: Securities Class Action Filed Against Rocket Pharmaceuticals (RCKT)
2025-07-10 ET
Investor Alert: Securities Class Action Filed Against Rocket Pharmaceuticals (RCKT)
2025-06-30 ET
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
2025-05-27 ET
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
2025-05-15 ET
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
2025-05-09 ET
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
2025-05-08 ET
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
2025-04-03 ET
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
2025-02-27 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
2025-01-02 ET
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-11 ET
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2024-12-10 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2024-11-26 ET
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
2024-11-18 ET
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
2024-11-12 ET
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
2024-11-08 ET
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
2024-09-17 11:00 ET
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
2024-09-10 11:00 ET
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
2024-08-27 11:00 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-08-05 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
2024-06-28 11:27 ET
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
2024-05-29 11:00 ET
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
2024-05-10 10:00 ET
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2024-05-06 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
2024-04-02 10:00 ET
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
2024-03-26 20:01 ET
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
2024-02-26 21:01 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
2024-02-13 12:00 ET
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2024-01-02 21:01 ET
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 12:00 ET
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
2023-11-06 21:04 ET
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
2023-10-19 11:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2023-10-02 11:00 ET
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
2023-09-26 20:01 ET
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference
2023-09-13 04:01 ET
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2023-09-12 20:02 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-09-12 20:01 ET
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
2023-09-06 20:05 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-08-10 11:00 ET
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
2023-06-08 11:00 ET
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
2023-05-31 11:00 ET
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
2023-05-23 11:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
2023-05-19 10:00 ET
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2023-05-09 11:00 ET
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
2023-05-04 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
2023-05-03 20:01 ET
Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
2023-04-11 20:01 ET
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-04-04 20:01 ET
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
2023-03-01 21:01 ET
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
2023-02-27 21:01 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
2023-02-09 21:01 ET
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
2023-02-07 12:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
2023-01-09 21:01 ET
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
2023-01-03 21:01 ET
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-22 11:00 ET
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
2022-12-12 15:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
2022-12-01 21:01 ET
Rocket Pharmaceuticals Completes Acquisition of Renovacor
2022-11-21 13:00 ET
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
2022-11-03 20:01 ET
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
2022-11-03 13:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
2022-10-12 10:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2022-10-10 12:00 ET
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
2022-10-04 03:21 ET
 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2022-10-03 20:42 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2022-09-30 10:00 ET
 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
2022-09-27 12:00 ET
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
2022-09-20 10:00 ET
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
2022-09-16 12:00 ET
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
2022-09-06 12:00 ET
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-08 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
2022-07-27 11:00 ET
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
2022-07-08 11:00 ET
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
2022-05-19 10:00 ET
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2022-05-16 10:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
2022-05-11 11:00 ET
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
2022-05-05 20:01 ET
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
2022-04-27 11:00 ET
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
2022-03-29 11:00 ET
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
2022-03-14 11:00 ET
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
2022-03-08 12:00 ET
Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
2022-02-24 12:00 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
2022-02-10 12:00 ET
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
2022-01-11 12:00 ET
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
2022-01-04 12:00 ET
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-13 14:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-12-08 12:00 ET
Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer
2021-12-07 12:00 ET
Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET to Discuss Updated Clinical Data Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-22 12:00 ET
Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference
2021-11-15 12:00 ET
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
2021-11-11 12:00 ET
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
2021-11-10 12:00 ET
Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference
2021-11-08 10:00 ET
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021
2021-11-04 13:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-11-03 11:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
2021-10-20 07:00 ET
Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2021-10-19 10:00 ET
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
2021-10-07 11:00 ET
Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa
2021-09-30 11:00 ET
Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
2021-09-14 11:00 ET
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
2021-09-10 11:00 ET
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
2021-09-07 11:00 ET
Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer
2021-08-30 11:00 ET
Rocket Pharmaceuticals Announces $26.4 Million Private Placement
2021-08-16 11:00 ET
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
2021-08-09 20:01 ET
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress
2021-08-03 20:01 ET
Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent Business Highlights
2021-05-13 11:00 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy
2021-05-10 20:00 ET
Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress
2021-04-27 20:30 ET
Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
2021-04-14 11:00 ET
Rocket Pharmaceuticals Reports Positive Long-Term Clinical Data from RP-L201 Trial for the Treatment of Leukocyte Adhesion Deficiency-I at the Clinical Immunology Society 2021 Annual Meeting
2021-03-29 11:00 ET
Rocket Pharmaceuticals Receives EMA Priority Medicines (PRIME) Designation for RP-L201 Gene Therapy for Treatment of Leukocyte Adhesion Deficiency-I
2021-03-22 11:00 ET
Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency
2021-03-09 12:00 ET
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I
2021-02-25 12:00 ET
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
2021-02-18 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2021-01-11 12:00 ET
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline
2021-01-06 12:00 ET
Rocket Pharmaceuticals Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-14 21:01 ET
Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2020-12-10 04:32 ET
Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock
2020-12-09 12:51 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-12-08 21:00 ET
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
2020-12-07 19:30 ET
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting
2020-12-06 15:00 ET
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting
2020-12-02 12:00 ET
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual Meeting
2020-11-24 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-11-13 12:00 ET
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis
2020-11-04 15:37 ET
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting
2020-11-04 12:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Progress
2020-10-16 11:00 ET
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
2020-10-01 11:00 ET
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 Meeting
2020-09-24 11:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-09-04 11:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-09-02 11:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease
2020-08-27 11:00 ET
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
2020-08-26 11:00 ET
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of Excellence
2020-08-05 11:00 ET
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress
2020-07-13 11:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2020-06-29 11:00 ET
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis
2020-06-08 11:00 ET
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
2020-05-26 11:00 ET
Rocket Pharmaceuticals Announces Participation at the Jefferies Virtual Healthcare Conference
2020-05-12 11:00 ET
Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
2020-05-06 11:00 ET
Rocket Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Progress
2020-05-05 11:00 ET
Rocket Pharmaceuticals Announces Participation at the BofA Securities 2020 Health Care Conference
2020-04-22 11:00 ET
Rocket Pharmaceuticals Appoints Elisabeth Bjӧrk, M.D., Ph.D. to Board of Directors
2020-04-02 13:00 ET
Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic
2020-04-02 11:30 ET
Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
2020-03-19 11:00 ET
Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
2020-03-05 12:00 ET
Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights
2020-02-24 12:00 ET
Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia
2020-02-18 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2020-02-11 14:15 ET
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
2020-02-06 12:00 ET
Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness
2020-01-06 12:00 ET
Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-16 12:00 ET
Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia
2019-12-13 21:01 ET
Rocket Pharmaceuticals Announces Closing of Public Offering
2019-12-11 03:45 ET
Rocket Pharmaceuticals Prices Public Offering of Common Stock
2019-12-10 21:01 ET
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
2019-12-09 12:00 ET
Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
2019-12-08 23:00 ET
Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
2019-12-06 12:00 ET
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia
2019-12-05 12:00 ET
Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting
2019-11-27 12:00 ET
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
2019-11-07 12:00 ET
Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
2019-11-06 14:00 ET
Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting
2019-11-05 12:00 ET
Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit
2019-10-24 11:00 ET
Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia
2019-10-22 11:00 ET
Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2019-10-15 11:00 ET
Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress
2019-10-01 11:00 ET
Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference
2019-09-23 11:00 ET
 Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
2019-09-10 11:00 ET
Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

SEC forms

Show financial reports only

SEC form 8
2026-09-15 11:06 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 8
2026-09-15 11:06 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 8
2026-08-10 20:17 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 8
2026-08-10 20:17 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 10
2026-08-10 20:05 ET
Rocket Pharmaceuticals reported for 2026 q2
SEC form 8
2026-08-03 11:41 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 8
2026-08-03 11:41 ET
Rocket Pharmaceuticals published news for 2026 q2
SEC form 8
2026-06-12 07:10 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 8
2026-06-12 07:10 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 20:45 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 20:45 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 10
2026-05-07 20:06 ET
Rocket Pharmaceuticals reported for 2026 q1
SEC form 8
2026-04-28 07:34 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 8
2026-04-28 07:34 ET
Rocket Pharmaceuticals published news for 2026 q1
SEC form 8
2026-03-27 11:32 ET
Rocket Pharmaceuticals published news for 2025 q4
SEC form 8
2026-03-27 11:32 ET
Rocket Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-26 16:21 ET
Rocket Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-26 16:21 ET
Rocket Pharmaceuticals published news for 2025 q4
SEC form 10
2026-02-26 16:06 ET
Rocket Pharmaceuticals reported for 2025 q4
SEC form 10
2025-11-06 16:06 ET
Rocket Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-06 16:04 ET
Rocket Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-06 16:04 ET
Rocket Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-14 11:09 ET
Rocket Pharmaceuticals published news for 2025 q3
SEC form 8
2025-10-14 11:09 ET
Rocket Pharmaceuticals published news for 2025 q3
SEC form 8
2025-09-17 20:15 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-17 20:15 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-17 20:15 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-20 11:11 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-20 11:11 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 10
2025-08-07 20:06 ET
Rocket Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-07 20:02 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-07 20:02 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-24 11:10 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-24 11:10 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-17 11:46 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-17 11:46 ET
Rocket Pharmaceuticals published news for 2025 q2
SEC form 8
2025-05-27 11:40 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-27 11:40 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-15 20:57 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-08 20:02 ET
Rocket Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Rocket Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Rocket Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-27 21:01 ET
Rocket Pharmaceuticals reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Rocket Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-07 16:45 ET
Rocket Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-07 16:20 ET
Rocket Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-07 16:20 ET
Rocket Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:15 ET
Rocket Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Rocket Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-05 00:00 ET
Rocket Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-05 00:00 ET
Rocket Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-07 16:05 ET
Rocket Pharmaceuticals reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
Rocket Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-06 17:26 ET
Rocket Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-06 17:26 ET
Rocket Pharmaceuticals published news for 2024 q1
SEC form 10
2024-02-27 16:05 ET
Rocket Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Rocket Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-26 00:00 ET
Rocket Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-26 00:00 ET
Rocket Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-07 16:40 ET
Rocket Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Rocket Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-09 17:21 ET
Rocket Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Rocket Pharmaceuticals reported for 2023 q2
SEC form 6
2023-06-23 16:27 ET
Rocket Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Rocket Pharmaceuticals reported for 2023 q1
SEC form 6
2023-04-04 17:14 ET
Rocket Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-10 11:59 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 17:31 ET
Rocket Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Rocket Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-27 17:22 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-07 16:50 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-09 16:29 ET
Rocket Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-22 16:06 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-01 16:31 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-04 16:07 ET
Rocket Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-04 00:00 ET
Rocket Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-03 17:10 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-04 17:28 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 16:38 ET
Rocket Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-20 16:52 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-09 08:21 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:28 ET
Rocket Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Rocket Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-08 17:17 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
Rocket Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 21:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-15 16:41 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-06 16:05 ET
Rocket Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Rocket Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
Rocket Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-11 19:09 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-09 16:53 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 18:40 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 16:10 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 17:19 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:32 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:03 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:02 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-16 21:02 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-08 16:43 ET
Rocket Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-08 18:53 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-05 16:13 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 16:02 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 21:49 ET
Rocket Pharmaceuticals published news for 2021 q3
SEC form 6
2021-08-30 07:10 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 16:20 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-09 16:11 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-09 00:00 ET
Rocket Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-21 16:28 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 16:46 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-10 16:42 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 16:22 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-27 16:18 ET
Rocket Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-01 17:03 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-07 06:02 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 20:19 ET
Rocket Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-11 08:22 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-11 08:16 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-09 08:24 ET
Rocket Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 16:08 ET
Rocket Pharmaceuticals published news for 2020 q3